As of Friday close, Pacific Biosciences of California Inc.’s (NASDAQ:PACB) stock was down -$0.54, moving down -6.11 percent to $8.30. The average number of shares traded per day over the past five days has been 5,002,540 shares. 1 time new highs have been achieved over the past 5 days. In the last twenty days, the average volume was 4,085,920, while in the previous 50 days, it was 4,435,400.
Since last month, PACB stock retreated -25.16%. Shares of the company fell to $8.01 on 03/10/23, the lowest level in the past month. A 52-week high of $14.20 was reached on 01/18/23 after having rallying from a 52-week low of $3.85. Since the beginning of this year, PACB’s stock price has risen by 1.47% or $0.12, and marked a new high 8 times. However, the stock has declined by -41.55% since its 52-week high.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
PACB stock investors should be aware that Pacific Biosciences of California Inc. (PACB) stock had its last reported insider trading activity 3 days ago on Mar 15. Ericson William W., the Director of the company, disposed of 7,541 shares for $8.90 on Mar 15. It resulted in a $67,115 divestment by the insider. HENRY CHRISTIAN O sold 13,769 shares at an average price of $9.49 on Mar 03. The insider now owns 1,222,939 shares following the transaction. On Mar 03, Van Oene Mark sold 6,268 shares at $9.49 apiece. The transaction was valued at $59,502.
The stock’s beta is 1.64. Besides these, the trailing price-to-sales (P/S) ratio of 16.89, the price-to-book (PB) ratio of 3.33.
In the three months ended September 29, Pacific Biosciences of California Inc.’s quick ratio stood at 3.00, while its current ratio was 3.20, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 1.59, and the total debt-to-equity ratio was 1.59. On the profitability front, the trailing twelve-month gross margin is 41.10% percent. Based on annual data, PACB earned $49.03 million in gross profit and brought in $128.3 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -21.00%. Return on equity (ROE) for the past 12 months was -48.20%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. PACB’s revenue fell -31.26% to $32.31 million during the quarter, while net income inched up to $27.35 million. While analysts expected Pacific Biosciences of California Inc. to report -$0.33 quarterly earnings, the actual figure was -$0.34 per share, beating the consensus estimate by -3.00%. During the quarter, the company generated -$83.69 million in EBITDA. The liabilities of Pacific Biosciences of California Inc. were 1.2 billion at the end of its most recent quarter ended September 29, and its total debt was $948.3 million. The value of shareholders’ equity is $247.08 million.
This quick technical analysis looks at Pacific Biosciences of California Inc.’s (PACB) price momentum. With a historical volatility rate of 55.00%, the RSI 9-day stood at 35.94% on 17 March.
At present, PACB shares trade -23.15% below its 20-day simple moving average and +6.82% percent above its 100-day simple moving average. However, the stock is currently trading approximately +0.36% above its SMA50 and +47.42% above its SMA200.
Stochastic coefficient K was 36.35% and Stochastic coefficient D was 40.54%, while ATR was 0.64. Given the Stochastic reading of 14.57% for the 14-day period, the RSI (14) reading has been calculated as 38.58%. As of today, the MACD Oscillator reading stands at -0.01, while the 14-day reading stands at -0.19.
With a median target price of $12.50, the current consensus forecast for the stock is $10.00 – $14.00. Based on these forecasts, analysts predict Pacific Biosciences of California Inc. (PACB) will achieve an average price target of $12.13.